Media stories about OPKO Health (NASDAQ:OPK) have been trending positive on Sunday, Accern reports. The research firm ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. OPKO Health earned a media sentiment score of 0.26 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 46.5887600797263 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the news articles that may have impacted Accern Sentiment’s analysis:
- OPKO Health (OPK) to Address Draft Local Coverage Determination Published by Novitas Solutions for 4Kscore Test (Earlier) (streetinsider.com)
- OPKO Plans to Address Draft Local Coverage Determination Published by Novitas Solutions for 4Kscore Test (finance.yahoo.com)
- Here’s Why OPKO Health Dropped as Much as 23% Today (fool.com)
- Smart Inhaler Market Global Players 2025: OPKO Health Inc, Teva Pharmaceuticals Industries Ltd., AstraZeneca plc … (theexpertconsulting.com)
- Identify Profitable Stock with Report of – OPKO Health, Inc. (NASDAQ:OPK) (finherald.com)
OPKO Health opened at $3.99 on Friday, according to MarketBeat.com. OPKO Health has a fifty-two week low of $2.66 and a fifty-two week high of $7.25. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.10 and a quick ratio of 0.94. The company has a market capitalization of $2.73 billion, a price-to-earnings ratio of -13.76 and a beta of 1.59.
OPK has been the subject of several research analyst reports. BidaskClub upgraded OPKO Health from a “strong sell” rating to a “sell” rating in a report on Friday, January 26th. Zacks Investment Research cut OPKO Health from a “hold” rating to a “sell” rating in a report on Friday, February 9th. Cantor Fitzgerald set a $20.00 price objective on OPKO Health and gave the stock a “buy” rating in a report on Thursday, March 1st. JPMorgan Chase cut OPKO Health from a “neutral” rating to an “underweight” rating and set a $7.00 price objective for the company. in a report on Friday, March 2nd. Finally, ValuEngine cut OPKO Health from a “sell” rating to a “strong sell” rating in a report on Thursday, March 1st. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $10.21.
In other news, Director Robert Scott Fishel bought 12,500 shares of the stock in a transaction dated Wednesday, April 25th. The stock was bought at an average price of $2.97 per share, for a total transaction of $37,125.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Phillip Md Et Al Frost bought 172,500 shares of the stock in a transaction dated Wednesday, February 21st. The stock was purchased at an average price of $3.63 per share, with a total value of $626,175.00. Following the purchase, the chief executive officer now owns 3,068,951 shares in the company, valued at $11,140,292.13. The disclosure for this purchase can be found here. In the last 90 days, insiders bought 1,609,367 shares of company stock valued at $5,053,787. 40.19% of the stock is currently owned by company insiders.
OPKO Health Company Profile
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.
Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.